Fairmount Funds Management LLC
CIK: 0001802528
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (12)
Alaunos Therapeutics, Inc.
Korsana Biosciences, Inc.
Apogee Therapeutics, Inc.
CRESCENT BIOPHARMA, INC.
Oruka Therapeutics, Inc.
Spyre Therapeutics, Inc.
Jade Biosciences, Inc.
Viridian Therapeutics, Inc.\DE
Zenas BioPharma, Inc.
Damora Therapeutics, Inc.
Cogent Biosciences, Inc.
Dianthus Therapeutics, Inc. /DE/
Discretionary Trading P&L
Holdings
Transaction History (49 total)
- Sep 9, 2026KRSA
Korsana Biosciences, Inc.
Award(A)IndirectStock Option (Right to Buy)
48.4K shares- - Sep 3, 2026APGE
Apogee Therapeutics, Inc.
Disposition(D)Indirect51.2K shares- - Sep 3, 2026APGE
Apogee Therapeutics, Inc.
Disposition(D)Indirect51.2K shares- - Sep 3, 2026APGE
Apogee Therapeutics, Inc.
Disposition(D)Indirect340.9K shares- - Aug 7, 2026APGE
Apogee Therapeutics, Inc.
Exercise(M)Indirect31.8K shares at avg. $17.00$541K - Aug 7, 2026APGE
Apogee Therapeutics, Inc.
Exercise(M)Indirect10.4K shares at avg. $43.85$455K - Jul 16, 2026CBIO
CRESCENT BIOPHARMA, INC.
Purchase(P)Indirect853.5K shares at avg. $14.50$12.4M - Jul 1, 2026ORKA
Oruka Therapeutics, Inc.
Sale(S)Indirect3.6M shares at avg. $84.43$300.0M - Jul 1, 2026ORKA
Oruka Therapeutics, Inc.
Conversion(C)Indirect3.6M shares- - Jun 23, 2026SYRE
Spyre Therapeutics, Inc.
Sale(S)Indirect4.7M shares at avg. $85.31$399.7M - Jun 23, 2026SYRE
Spyre Therapeutics, Inc.
Conversion(C)Indirect666.7K shares- - Jun 9, 2026APGE
Apogee Therapeutics, Inc.
Award(A)IndirectStock Option (Right to Buy)
7.7K shares- - Jun 9, 2026JBIO
Jade Biosciences, Inc.
Award(A)DirectStock Option (Right to Buy)
34.8K shares- - Jun 2, 2026CBIO
CRESCENT BIOPHARMA, INC.
Award(A)IndirectStock Option (Right to Buy)
11.1K shares- - Jun 2, 2026ORKA
Oruka Therapeutics, Inc.
Award(A)IndirectStock Option (Right to Buy)
9.1K shares- - May 27, 2026SYRE
Spyre Therapeutics, Inc.
Award(A)IndirectStock Option (Right to Buy)
8K shares- - May 11, 2026VRDN
Viridian Therapeutics, Inc.\DE
Purchase(P)Indirect1.2M shares at avg. $17.00$20.0M - Mar 31, 2026ZBIO
Zenas BioPharma, Inc.
Purchase(P)Indirect150K shares at avg. $20.00$3.0M - Mar 23, 2026DMRA
Damora Therapeutics, Inc.
Award(A)IndirectStock Option (right to buy)
37.3K shares- - Feb 9, 2026GLTO
Galecto, Inc.
Exercise(M)Indirect5.8M shares- - Feb 9, 2026GLTO
Galecto, Inc.
Exercise(M)Indirect2.9M shares- - Jan 22, 2026COGT
Cogent Biosciences, Inc.
Sale(S)Indirect3.5M shares at avg. $36.40$127.4M - Jan 22, 2026APGE
Apogee Therapeutics, Inc.
Sale(S)Indirect1.8M shares at avg. $76.30$133.5M - Dec 4, 2025CBIO
CRESCENT BIOPHARMA, INC.
Purchase(P)Indirect1.4M shares at avg. $13.41$18.2M - Oct 23, 2025VRDN
Viridian Therapeutics, Inc.\DE
Purchase(P)Indirect454.5K shares at avg. $22.00$10.0M
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 9, 2026 | KRSA Korsana Biosciences, Inc. | Award(A) Stock Option (Right to Buy) | 48,445 | - | - | Indirect |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Disposition(D) | 51,166 | - | $0 | Indirect |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Disposition(D) | 51,166 | - | $0 | Indirect |
| Sep 3, 2026 | APGE Apogee Therapeutics, Inc. | Disposition(D) | 340,855 | - | $0 | Indirect |
| Aug 7, 2026 | APGE Apogee Therapeutics, Inc. | Exercise(M) | 31,838 | $17.00 | $541,246 | Indirect |
| Aug 7, 2026 | APGE Apogee Therapeutics, Inc. | Exercise(M) | 10,370 | $43.85 | $454,725 | Indirect |
| Jul 16, 2026 | CBIO CRESCENT BIOPHARMA, INC. | Purchase(P) | 853,450 | $14.50 | $12,375,025 | Indirect |
| Jul 1, 2026 | ORKA Oruka Therapeutics, Inc. | Sale(S) | 3,553,410 | $84.43 | $300,014,406 | Indirect |
| Jul 1, 2026 | ORKA Oruka Therapeutics, Inc. | Conversion(C) | 3,553,410 | - | $0 | Indirect |
| Jun 23, 2026 | SYRE Spyre Therapeutics, Inc. | Sale(S) | 4,684,781 | $85.31 | $399,658,667 | Indirect |
| Jun 23, 2026 | SYRE Spyre Therapeutics, Inc. | Conversion(C) | 666,680 | - | $0 | Indirect |
| Jun 9, 2026 | APGE Apogee Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 7,657 | - | - | Indirect |
| Jun 9, 2026 | JBIO Jade Biosciences, Inc. | Award(A) Stock Option (Right to Buy) | 34,843 | - | - | Direct |
| Jun 2, 2026 | CBIO CRESCENT BIOPHARMA, INC. | Award(A) Stock Option (Right to Buy) | 11,050 | - | - | Indirect |
| Jun 2, 2026 | ORKA Oruka Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 9,136 | - | - | Indirect |
| May 27, 2026 | SYRE Spyre Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 8,026 | - | - | Indirect |
| May 11, 2026 | VRDN Viridian Therapeutics, Inc.\DE | Purchase(P) | 1,176,470 | $17.00 | $19,999,990 | Indirect |
| Mar 31, 2026 | ZBIO Zenas BioPharma, Inc. | Purchase(P) | 150,000 | $20.00 | $3,000,000 | Indirect |
| Mar 23, 2026 | DMRA Damora Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 37,313 | - | - | Indirect |
| Feb 9, 2026 |  GLTO Galecto, Inc. | Exercise(M) | 5,809,000 | - | $0 | Indirect |
| Feb 9, 2026 | GLTO Galecto, Inc. | Exercise(M) | 2,904,000 | - | $0 | Indirect |
| Jan 22, 2026 | COGT Cogent Biosciences, Inc. | Sale(S) | 3,500,000 | $36.40 | $127,400,000 | Indirect |
| Jan 22, 2026 | APGE Apogee Therapeutics, Inc. | Sale(S) | 1,750,000 | $76.30 | $133,525,000 | Indirect |
| Dec 4, 2025 | CBIO CRESCENT BIOPHARMA, INC. | Purchase(P) | 1,360,000 | $13.41 | $18,237,600 | Indirect |
| Oct 23, 2025 | VRDN Viridian Therapeutics, Inc.\DE | Purchase(P) | 454,545 | $22.00 | $9,999,990 | Indirect |
1-25 of 49 transactions
About Fairmount Funds Management LLC
Fairmount Funds Management LLC (SEC CIK 0001802528) files insider reports with the SEC as Director of Alaunos Therapeutics, Inc. (TCRT), Director of Korsana Biosciences, Inc. (KRSA) and Director of Apogee Therapeutics, Inc. (APGE). Signal8 also holds filings tied to 9 other companies.
Signal8 holds 43 ownership filings by Fairmount Funds Management LLC (7 Form 3, 36 Form 4), filed between Sep 6, 2024 and Oct 15, 2026. Those filings report 49 transactions, from Sep 11, 2024 to Sep 9, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Fairmount Funds Management LLC's filings is in WEST CONSHOHOCKEN, PA.
Recent filings by Fairmount Funds Management LLC
- Sep 9, 2026: Grant or award of KRSA derivative securities (Form 4, code A).
- Sep 3, 2026: Disposition to issuer transactions of APGE shares (3 lines, Form 4, code D).
- Aug 7, 2026: Option exercises of APGE shares (2 lines, Form 4, code M).
- Jul 16, 2026: Open-market purchase of CBIO shares (Form 4, code P).
- Jul 1, 2026: Open-market sale of ORKA shares (Form 4, code S).
Other insiders filing for Alaunos Therapeutics, Inc. (TCRT)
- Weis Holger, CEO
- Vieser Jaime, Director
- Postma Robert W, Director
- Jerman Michael Allen, Director
- Groenewald Ferdinand, VP, Finance
- Hogue Dale Curtis Jr.